NEW YORK (GenomeWeb News) – Atossa Genetics today said that McKesson Medical-Surgical will distribute and sell the firm's MASCT device and patient collection kits.

The device and kits are used in OB/GYN, primary care, and women's health clinics for non-invasive collection of breast fluid. The sample is then analyzed by an Atossa subsidiary with the firm's ForeCYTE Breast Health Test, which assesses future risk of breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.